Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced receiving a notification of the Intent to Grant a European Patent for treatments related to Clostridioides difficile associated disease. This patent, numbered 14784945.9, focuses on methods and compositions for both treatment and prevention of the infection. Alongside patents in Australia, New Zealand, and the U.S., this grant strengthens Immuron's intellectual property in an area with significant health and economic impact, as Clostridioides difficile infections can result in severe complications and considerable healthcare costs globally.

Positive

• Received Intent to Grant European Patent 14784945.9 for Clostridioides difficile treatment methods.
• Strengthens patent portfolio alongside existing patents in Australia, New Zealand, and the U.S.

Negative

• None.

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.

Notification of the intent to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was received from the European Patent Office.

The European registration once formally granted will add to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the United States.

Clostridioides difficile (previously known as Clostridium difficile) infection (CDI) is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile. CDI can also result in serious disease complications including bowel perforation, toxic megacolon and sepsis, and it can prove fatal in the most severe cases. In recent years, increases in the frequency and severity of CDI have been observed worldwide, as well as an increased risk of community-associated CDI, and CDI in persons previously thought to be low risk. It is estimated that CDI affects up to 1.2% of hospitalized patients in the United States, representing an estimated cost of USD 4.8 billion per year (source: CDC). In Europe, the estimated cost is approximately 3 billion per year, which is likely to increase concomitantly with a more elderly society; more than 134 million Europeans will be >65 years by 2050.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com

 

FAQ

What is the significance of the European Patent granted to Immuron (IMRN)?

The European Patent enhances Immuron's intellectual property for the treatment of Clostridioides difficile associated disease, supporting its market position in Europe.

What disease does the patent related to Immuron (IMRN) focus on?

Clostridioides difficile associated disease, which is a severe infection impacting the large intestine.

How much does <em>Clostridioides difficile</em> infection cost the healthcare system?

In the U.S., the estimated annual cost of Clostridioides difficile infection is approximately USD 4.8 billion.

What is the patent number for Immuron's European Patent?

The patent number is 14784945.9.

Does Immuron (IMRN) have patents in other regions apart from Europe?

Yes, Immuron also has patents in Australia, New Zealand, and the United States.